ASCO 2021 | How low can we go? Treating ER+ and TNBC with HER2-targeting agents
New early-phase trial data is starting to show that HER2-targeting agents elicit clinical benefits for patients with low HER2 expression, leading to the question, ‘how low can we go?’. Guy Jerusalem, MD, PhD, Domaine Universitaire du Sart Tilman, Liège, Belgium, discusses how the indications for HER2-targeting agents are evolving beyond just patients with HER2-overexpressing tumors, to individuals with estrogen receptor (ER)-positive and triple negative breast cancer who show small amounts of HER2 expression. Dr Jerusalem highlights the need for standardization of tests to detect HER2-positivity and in-depth investigations into how different agents work in these populations. Evidence from Phase III trials comparing HER2-agents to standard of care in a randomized fashion will be important in addressing this question. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Dr. Jerusalem reports personal fees and non-financial support from Novartis, during the conduct of the study: grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal feed and non-financial support from Pfizer, personal fees and non-financial support from Lilly, personal fees and non-financial support from Amgen, personal fees and non-financial support from BMS, personal feed and non-financial support from Astra-Zeneca, personal fees from Daiichi Sankyo, personal fees from Abbvie, non-financial support from Medimmune, non-financial support from MerckKGaA.
